Advanced search
Start date
Betweenand

Development of vaccine against COVID-19

Grant number: 20/10127-1
Support type:Research Grants - Research in Public Policies
Duration: September 01, 2020 - August 31, 2022
Field of knowledge:Health Sciences - Collective Health - Public Health
Principal researcher:Dimas Tadeu Covas
Grantee:Dimas Tadeu Covas
Home Institution: Instituto Butantan. Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
Assoc. researchers:Cristiano Gonçalves Pereira ; Débora Botéquio Moretti ; Esper Georges Kallás ; Raul Machado Neto ; Ricardo Palacios Gomez ; Rui Curi

Abstract

After months of the worldwide spread of the SARS-CoV-2 novel coronavirus, it has become clear that the development and manufacturing of a safe and effective vaccine is a promising public policy strategy to combat the pandemic that will allow for the complete reopening of the economy and the prevention of new epidemic waves. Instituto Butantan is a century-old institution dedicated to the development of biological medicines and is responsible for providing 65% of all vaccines and 100% of antivenoms to the public health system in Brazil. Considering the Institute's standing, sustainability and ability to rapidly respond to specific health challenges of the population, it has attracted partnerships with the main developers of immunobiologicals in the world for the development and manufacturing of vaccine candidates for COVID-19. The agreement signed between Instituto Butantan and Sinovac Biotech Ltd to carry out a Phase III clinical trial and subsequent manufacturing of the vaccine developed by the Chinese company is relevant due to the effectiveness demonstrated by the inactivated vaccine in the Phase I and II trials and because it is a traditional and widely used technology. FAPESP, has a recognized role in the production of knowledge and new technologies and is fundamental in the search of solutions to urgent issues. The relationship that will be established between Instituto Butantan and FAPESP to support activities involving the development and licensing of the inactivated vaccine against COVID-19 gears towards the establishing of pandemic control and mitigation policies that impact the health and social and economic conditions of the country. (AU)

Articles published in Pesquisa FAPESP Magazine about the research grant:
Las vacunas en el mundo real 
Vaccines in the real world 
Una ciudad convertida en laboratorio 
A town turned laboratory 
Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
SLAVOV, SVETOSLAV N.; PATANE, JOSE S. L.; BEZERRA, RAFAEL DOS SANTOS; GIOVANETTI, MARTA; FONSECA, VAGNER; MARTINS, ANTONIO J.; VIALA, VINCENT L.; RODRIGUES, EVANDRA S.; SANTOS, ELAINE V.; BARROS, CLAUDIA R. S.; MARQUEZE, ELAINE C.; SANTOS, BIBIANA; ABURJAILE, FLAVIA; NETO, RAUL M.; MORETTI, DEBORA B.; HADDAD, RICARDO; CALADO, RODRIGO T.; KITAJIMA, JOAO P.; FREITAS, ERIKA; SCHLESINGER, DAVID; JUNIOR DE ALCANTARA, LUIZ C.; ELIAS, MARIA C.; SAMPAIO, SANDRA C.; KASHIMA, SIMONE; COVAS, DIMAS T. Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 (beta) variant (20H/501Y.V2) in Brazil. Journal of Medical Virology, v. 93, n. 12 JUL 2021. Web of Science Citations: 2.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.